Author

P. L. Anderson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:non-human primate· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Organism:human· 1

Frequent Co-Authors

L. R. Bushman· 3 shared A. Grattoni· 2 shared C. Y. X. Chua· 2 shared F. P. Pons-Faudoa· 2 shared J. E. Nichols· 2 shared J. T. Kimata· 2 shared K. A. Shelton· 2 shared P. N. Nehete· 2 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

L. R. Bushman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates

F. P. Pons-Faudoa, N. Di Trani, S. Capuani, J. N. Campa-Carranza, B. Nehete, S. Sharma, K. A. Shelton, L. R. Bushman, F. Abdelmawla, M. Williams, L. Roon, D. Nerguizian, C. Y. X. Chua, M. M. Ittmann, J. E. Nichols, , A. Grattoni

An ultra-long-acting refillable nanofluidic implant sustained islatravir levels in non-human primates for 20 months and provided 100% protection against SHIV infection.

bioRxiv · Dec 15, 2022 · PreprintBioengineering

Pharmacokinetics of Orally Administered GS-441524 in Dogs

V. C. Yan, C.-D. Pham, M. J. Yan, A. J. Yan, S. Khadka, K. Arthur, J. J. Ackroyd, D. K. Georgiou, L. E. Roon, L. R. Bushman, P. L. Anderson, C. Li, F. L. Muller

This study evaluates the oral bioavailability of GS-441524 in dogs, showing sustained plasma concentrations above the EC50 for SARS-CoV-2.

bioRxiv · Feb 4, 2021 · PreprintPharmacology & Toxicology

Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates

F. P. Pons-Faudoa, A. Sizovs, K. A. Shelton, Z. Momin, L. R. Bushman, J. Xu, C. Y. X. Chua, J. E. Nichols, T. Hawkins, J. F. Rooney, M. A. Marzinke, J. T. Kimata, P. L. Anderson, P. N. Nehete, R. C. Arduino, , A. Grattoni

This study evaluates a long-acting tenofovir alafenamide nanofluidic implant in nonhuman primates, showing partial protection against SHIV infection.

bioRxiv · May 13, 2020Bioengineering

Cryopreservation of human mucosal tissues

S. M. Hughes, A. L. Ferre, S. E. Yandura, C. Shetler, C. A. R. Baker, F. Calienes, C. N. Levy, R. D. Astronomo, Z. Shu, G. M. Lentz, M. Fialkow, A. C. Kirby, M. J. McElrath, E. Sinclair, L. C. Rohan, , F. Hladik

This study compares cryopreservation and vitrification protocols for human mucosal tissues, finding cryopreservation effective for cervicovaginal tissues but less so for colorectal tissues.

bioRxiv · May 30, 2018Immunology